6 months ago
NBIX
AnalystsAndrew S. FeinAndrew S. Fein's Stock Forecasts
AnalystsAndrew S. Fein
Analyst Ranking
Top 9%
#437 out of 5346 analysts
Average Return
+26.41%
Win Rate
61%44 out of 72
Risk vs Reward
Poor
Good
Andrew S. Fein's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Liquidia CorpLQDA | +294.66% | $22.86 | $90.22 | 2025-10-06 - 2026-08-07 | Buy |
Day One Biopharmaceuticals IncDAWN | +271.21% | $5.80 | $21.53 | 2025-08-06 - 2026-04-23 | Buy |
Palvella Therapeutics IncPVLA | +233.55% | $47.30 | $157.77 | 2025-08-15 - 2026-08-07 | Buy |
Liquidia CorpLQDA | +223.25% | $27.91 | $90.22 | 2025-11-04 - 2026-08-07 | Buy |
Palvella Therapeutics IncPVLA | +173.48% | $57.69 | $157.77 | 2025-09-25 - 2026-08-07 | Buy |
Andrew S. Fein Analyst Color
Get additional color on Andrew S. Fein's coverage of popular stocks
8 months ago
BCRX
Andrew S. Fein's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Biogen IncBIIB | 3 | Buy | $251.00 | +20.71% | Maintains | 11 days ago |
Liquidia CorpLQDA | 6 | Buy | $130.00 | +44.09% | Maintains | 18 days ago |
Metavia IncMTVA | 5 | Buy | $20.00 | +1,242.28% | Reiterates | a month ago |
Biocryst Pharmaceuticals IncBCRX | 2 | Buy | $32.00 | +241.15% | Maintains | a month ago |
Fulcrum Therapeutics IncFULC | 4 | Hold | $3.00 | -22.88% | Downgrades | 2 months ago |
Catalyst Pharmaceuticals IncCPRX | 1 | Hold | $31.50 | +0.03% | Downgrades | 2 months ago |
Wave Life Sciences LtdWVE | 5 | Buy | $13.00 | +113.11% | Maintains | 3 months ago |
Madrigal Pharmaceuticals IncMDGL | 4 | Buy | $620.00 | +21.56% | Reiterates | 3 months ago |
Kalvista Pharmaceuticals IncKALV | 1 | Hold | $27.00 | 0.00% | Downgrades | 3 months ago |
Aura Biosciences IncAURA | 1 | Buy | $24.00 | +200.38% | Maintains | 3 months ago |
Protara Therapeutics IncTARA | 1 | Buy | $27.00 | +555.34% | Maintains | 3 months ago |
Neurocrine Biosciences IncNBIX | 3 | Buy | $215.00 | +31.57% | Maintains | 4 months ago |
United Therapeutics CorpUTHR | 3 | Buy | $660.00 | +22.49% | Maintains | 4 months ago |
Insmed IncINSM | 4 | Buy | $245.00 | +86.88% | Maintains | 4 months ago |
Denali Therapeutics IncDNLI | 1 | Buy | $42.00 | +69.15% | Maintains | 4 months ago |
Amylyx Pharmaceuticals IncAMLX | 3 | Buy | $34.00 | +48.99% | Reiterates | 5 months ago |
Palvella Therapeutics IncPVLA | 6 | Buy | $270.00 | +71.14% | Maintains | 5 months ago |
Vertex Pharmaceuticals IncVRTX | 4 | Buy | $641.00 | +29.22% | Maintains | 5 months ago |
Savara IncSVRA | 3 | Buy | $10.00 | +71.53% | Maintains | 8 months ago |
Dbv Technologies SaDBVT | 3 | Buy | $40.00 | +196.74% | Maintains | 8 months ago |
Kymera Therapeutics IncKYMR | 3 | Buy | $134.00 | +24.63% | Maintains | 8 months ago |
Kamada LtdKMDA | 1 | Buy | $13.00 | +78.82% | Maintains | 8 months ago |
Arcturus Therapeutics Holdings IncARCT | 3 | Hold | $9.00 | +21.46% | Maintains | 9 months ago |
Prothena Corp Public Ltd CoPRTA | 3 | Buy | $30.00 | +242.47% | Maintains | 9 months ago |
Akero Therapeutics IncAKRO | 2 | Hold | $54.00 | -1.19% | Downgrades | 10 months ago |
89bio IncETNB | 2 | Hold | $14.50 | -2.29% | Downgrades | a year ago |
Terns Pharmaceuticals IncTERN | 1 | Hold | $7.44 | -85.95% | Assumes | a year ago |
Arvinas IncARVN | 1 | Buy | $18.00 | N/A | Maintains | a year ago |
Day One Biopharmaceuticals IncDAWN | 1 | Buy | $25.00 | N/A | Maintains | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.